People with genetic disorders like xeroderma pigmentosum, damaged skin sites like scars, burn sites, immuno-compromised patients with suppressed immune system and undergoing organ transplantation are at high risk.
Ultraviolet-B radiation from sunlight and tanning salons are a major cause of CSCC contraction.
Some drugs like voriconazole and immunosuppressive therapies also cause CSCC.
Curcumin, being a potent anti-cancer agent obtained from the great Indian spice Turmeric, can surprisingly be very helpful in controlling the chances of CSCC development.
Curcumin C3 complex is a Curcumin supplement composed of 76.07% Curcumin, 20.28% Demethoxycurcumin and 3.63% Bisdemethoxycurcumin.
About the Study
Curcumin C3 complex was tested for its efficacy in controlling the incidence of UV-B induced cancer and the mechanism followed for the same.
Skin cells from JB6 mice were used for in vitro study and SKH-1 mice as model organisms for in vivo study were used.
For in vivo study, Curcumin C3 complex supplements were given orally to SKH-1 mice for 14 days.
They were then exposed to UV-B radiation and later killed after 24 hours.
The researchers collected their skin tissues and serum for analysis.
Skin cells from JB6 mice were taken, exposed to UV-B radiation after treating them with Curcumin C3 complex for 2 hours and the resulting effects were studied.
It was found that C3 treatment lead to a decrease in the proliferation of epidermal cells by decreasing the levels of fibroblast growth factor-2 (FGF-2) and reduced the UV-B induced enlargement of epidermal tissues caused by increased multiplication of its cells.
This condition is termed as hyperplasia and is a precancerous condition.
It also produced anti-cancer activity by blocking NF-kB and mTOR pathways.
What can we conclude
Curcumin has been found to be a promising anti-cancer agent in many animal and human studies.
This study conducted on mice indicates that the cancerous activity produced by Ultraviolet B radiation can be reversed by oral administration of Curcumin C3 complex.
It decreases the levels of FGF-2 and inhibits NF-kB and mTOR pathways leading to reduction in epidermal cell proliferation, differentiation and hyperplasia.